US 12,460,208 B2
Immunomodulatory polynucleotides and uses thereof
Yan Shao, Changchun (CN); and Li-Gong Wang, Changchun (CN)
Assigned to PARR BIOTECHNOLOGY CO., LTD., Shijiazhuang (CN)
Filed by Parr Biotechnology Co., Ltd., Shijiazhuang (CN)
Filed on May 6, 2022, as Appl. No. 17/662,392.
Application 17/662,392 is a continuation in part of application No. 16/484,090, granted, now 11,326,170, previously published as PCT/CN2018/083435, filed on Apr. 17, 2018.
Claims priority of application No. 201710251198.4 (CN), filed on Apr. 18, 2017.
Prior Publication US 2023/0203504 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/04 (2006.01); A61P 35/00 (2006.01); C07K 14/57 (2006.01); C12N 15/11 (2006.01); C12N 15/117 (2010.01); A61K 31/7115 (2006.01); A61K 45/06 (2006.01)
CPC C12N 15/117 (2013.01) [A61P 35/00 (2018.01); C07K 14/57 (2013.01); C12N 15/111 (2013.01); A61K 31/7115 (2013.01); A61K 45/06 (2013.01)] 19 Claims
 
1. A method for treating a cancer in a subject comprising:
administering to the subject a composition comprising a therapeutically effective amount of an immunomodulatory polynucleotide comprising a sequence of SEQ ID NO.: 6; and
administering to the subject a therapeutically effective amount of a targeted therapeutic against the cancer,
wherein the cancer is colorectal cancer, hepatocellular carcinoma, lymphocytic leukemia, or lymphoma.